Adeel M, et al. - In this retrospective study, researchers compared docetaxel plus cyclophosphamide (TC) vs doxorubicin plus cyclophosphamide (AC) as adjuvant chemotherapy when treating Pakistani breast cancer patients by validating those results with a published analysis of the same treatment given to US patients. One hundred eighty-nine patients out of 358 received TC (75 mg/m² of docetaxel, 600 mg/m² of cyclophosphamide) and 169 were treated with AC (60 mg/m² of doxorubicin, 600 mg/m² of cyclophosphamide) for four chemotherapy cycles between June 2015 and September 2017. There was no statistically significant difference in the proportions of patients treated with TC and AC in terms of vomiting, extreme fatigue, diarrhea, stability, mild anemia and overall survival. In comparison with AC, however, TC was less toxic in terms of weight loss, dizziness and sores in the throat and mouth, while AC was less toxic in terms of taste change, muscle pain, burning in hands and feet, changes in hemoglobin levels, moderate anemia and blood transfusion compared to TC. Investigators reported that TC was more toxic than AC at 27 months, while the overall survival rate of both combinations was the same.